Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proglumetacin SCHEMBL27106 | 0.91 | PTGS2 (0.59) | PTGS2 | |
| Proglumetacin SCHEMBL29384391 | 0.91 | PTGS2 (0.59) | PTGS2 | |
| Proglumetacin SCHEMBL1650599 | 0.88 | PTGS2 (0.56) | PTGS2 | |
| Proglumetacin SCHEMBL19642980 | 0.88 | PTGS2 (0.56) | PTGS2 | |
| Proglumetacin SCHEMBL99165 | 0.88 | PTGS2 (0.56) | PTGS2 | |
| Proglumetacin SCHEMBL28086382 | 0.88 | PTGS2 (0.55) | PTGS2 | |
| Proglumetacin SCHEMBL2070226 | 0.88 | PTGS2 (0.55) | PTGS2 | |
| SCHEMBL5077578 | 0.83 | PTGS2 (0.57) | PTGS2 | |
| Proglumetacin SCHEMBL13724384 | 0.82 | PTGS2 (0.49) | PTGS2 | |
| Proglumetacin SCHEMBL5482765 | 0.81 | PTGS2 (0.47) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | PTGS2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.